Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 May-Jun;15(3):451-459.
doi: 10.1016/j.jacl.2021.03.002. Epub 2021 Mar 6.

Association between antecedent statin use and severe disease outcomes in COVID-19: A retrospective study with propensity score matching

Prateek Lohia  1 , Shweta Kapur  2 , Sindhuri Benjaram  3 , Tanveer Mir  4
Affiliations
Multicenter Study

Association between antecedent statin use and severe disease outcomes in COVID-19: A retrospective study with propensity score matching

Prateek Lohia et al. J Clin Lipidol. 2021 May-Jun.

Abstract

Background: Statins have been associated with a reduction in inflammatory markers and improved endothelial function. Whether statins offer any benefit in COVID-19 needs to be elucidated.

Objective: To determine the association between antecedent statin use and severe disease outcomes among COVID-19 patients.

Methods: A retrospective cohort study on 1014 patients with confirmed COVID-19 diagnosis. Outcomes were mortality, need for mechanical ventilation, and intensive care admission. Patients were classified into statin-users vs statin non-users based on antecedent use of statins. Multivariable regression analysis was performed adjusting for confounders such as age, sex, race, BMI, smoking, insurance, and comorbidities. Propensity score matching was performed to achieve a 1:1 balanced cohort.

Results: A total of 1014 patients (Median age 65 (IQR 53-73); 530 (52.3%) males; 753 (74.3%) African Americans; median BMI 29.4 (IQR 25.1-35.9); 615 (60.7%) with Medicare insurance) were included in the study. About 454 patients (44.77%) were using statins as home medication. Antecedent statin use was associated with significant decrease in mortality in the total cohort (OR, 0.66; 95% CI, 0.46 - 0.95; p = 0.03). Among the propensity score matched (PSM) cohort of 466 patients (233 statin users and 233 statin non-users), all the baseline characteristics had similar distribution among the two groups. Statin users had significant reduction in mortality in the PSM cohort as well (OR, 0.56; 95% CI, 0.37 - 0.83; p = 0.004).

Conclusions: Statin use was associated with significant reduction in mortality among COVID-19 patients. These findings support the pursuit of randomized clinical trials to explore the possible benefits of statins in COVID-19.

Keywords: COVID-19; Critical care; Hydroxymethylglutaryl-CoA reductase inhibitors; Mechanical ventilation; Mortality.

PubMed Disclaimer

References

    1. Gu Q., Paulose-Ram R., Burt V.L., Kit B.K. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003–2012. NCHS Data Brief. 2014;177:1–8. - PubMed
    1. Episcopio D., Aminov S., Benjamin S. Atorvastatin restricts the ability of influenza virus to generate lipid droplets and severely suppresses the replication of the virus. FASEB J. 2019;33(8):9516–9525. - PMC - PubMed
    1. Fedson D.S. Treating influenza with statins and other immunomodulatory agents. Antivir Res. 2013;99(3):417–435. - PubMed
    1. Frost F.J., Petersen H., Tollestrup K., Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007;131(4):1006–1012. - PubMed
    1. Fedson D.S., Rordam O.M. Treating Ebola patients: a 'bottom up' approach using generic statins and angiotensin receptor blockers. Int J Infect Dis. 2015;36:80–84. - PubMed

Publication types

Substances